Endometrial Cancer · Surgical Staging + Fertility-Sparing
Surgical staging = hysterectomy + BSO + cytology ± sentinel node (better than systematic dissection), early minimally invasive; G1/IA without myometrial invasion young may have progestin fertility-sparing; high-risk add adjuvant.
High-risk/advanced → staging + adjuvant: High-risk/advanced (deep myometrial, high-grade, serous/clear cell, cervical or extrauterine involvement) → surgical staging (with omentect…
Step-by-step decision
Choose step by step as prompted; reaching an endpoint gives the management recommendation. You can go back a step or restart anytime.
Full pathway
- [Decision] Stage/grade + fertility wishGrade/myometrial invasion/spread? Fertility-sparing?
- Localized, planning surgery (any grade) → Surgical staging
- G1 endometrioid, IA without myometrial invasion, young strongly wanting fertility preservation → G1/IA no invasion → progestin fertility-sparing
- High-risk/advanced (deep myometrial/high-grade/serous-clear cell/cervical or extrauterine involvement) → High-risk/advanced → staging + adjuvant
- [End] Surgical stagingSurgical staging = total hysterectomy + bilateral salpingo-oophorectomy + peritoneal cytology ± nodal assessment (sentinel lymph node mapping is better than systematic dissection); early disease prefers minimally invasive (laparoscopic/robotic); adjuvant therapy by molecular classification (POLE/MMR-d/p53/NSMP) and pathology.
- [End] G1/IA no invasion → progestin fertility-sparingG1 endometrioid, IA without myometrial invasion, young strongly wanting fertility preservation → progestin (LNG-IUS/high-dose oral progestin) + close monitoring (D&C every 3-6 months); hysterectomy after completing childbearing; no response/progression → surgery.
- [End] High-risk/advanced → staging + adjuvantHigh-risk/advanced (deep myometrial, high-grade, serous/clear cell, cervical or extrauterine involvement) → surgical staging (with omentectomy/cytoreduction) + adjuvant (chemotherapy ± radiotherapy); multidisciplinary.
Source guidelines & references
- Endometrial cancer management (ESGO/ESTRO/ESP; NCCN; molecular classification POLE/MMR/p53)
This pathway is our own synthesis of the decision logic in the guidelines above (not the guideline verbatim); thresholds and workflows change as guidelines update — in practice follow the latest guideline, your institution's protocol and the individual patient.